ORXOY Stock News Orexo Ab (ORXOY) 16.9050 07/26/2014 17:14:0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Orexo Ab (ORXOY) 16.9050 $ORXOY

Age Related Memory Impairment Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tn8pmb/age_related) has announced the addition of the "Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" report to their offering. Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" provides data on the Age Related Memory Impairment clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Age Related Memory Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Age Related Memory Impairment. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Age Related Memory Impairment Therapeutics Clinical Trials - Orexo AB - Helicon Therapeutics, Inc. - Dart NeuroScience LLC - Targacept, Inc. - Martek Biosciences Corporation (Inactive) - Lexicon Pharmaceuticals, Inc. - Bayer AG - Allergan, Inc. - Accera, Inc. - Central Drug Research Institute - University of Cincinnati - The University of Arizona - University Hospital, Toulouse - University of California, Los Angeles - University of Southern California - National Institute on Aging - Queen's University - Stanford University - University of Florida For more information visit http://www.researchandmarkets.com/research/tn...ge_related

Actavis Confirms Generic Zubsolv® Patent Challenge
PR Newswire - Mon Jun 30, 6:30AM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv®, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.

Acute Pain - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlbxfm/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Nektar Therapeutics - Santen Pharmaceutical Co., Ltd. - Pacira Pharmaceuticals, Inc. - AcelRx Pharmaceuticals, Inc. - Laboratorios Del Dr. Esteve S.A. - Pfizer Inc. - Sigma-Tau S.p.A. - A. Menarini Industrie Farmaceutiche Riunite Srl - Anavex Life Sciences Corp. - Nuvo Research Inc. - Zalicus Inc. - Yungjin Pharm Ind. Co., Ltd. - Array BioPharma Inc. - Orexo AB - Insys Therapeutics, Inc. - Grunenthal GmbH - AngioChem Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - Syntrix Biosystems, Inc. - Kineta, Inc. - QRxPharma Limited - Cara Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - Encore Therapeutics Inc. - Madeira Therapeutics For more information visit http://www.researchandmarkets.com/research/qlbxfm/acute_pain

Orexo signs exclusive reimbursement agreement for ZUBSOLV with UnitedHealth Group and OptumRx
M2 - Wed Mar 12, 8:24AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced today the signing of a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of ZUBSOLV.

Orexo closes on new SEK200m revolving credit facility
M2 - Thu Dec 12, 6:47AM CST
Orexo AB (STO: ORX.ST), a specialty pharmaceutical company, announced today the closing of a SEK200m revolving credit facility with Danske Bank.

Orexo's Abstral launched in Japan
M2 - Thu Dec 12, 6:42AM CST
Orexo AB (STO:ORX.ST), a specialty pharmaceutical company, announced today the commencement of the Japanese launch of Abstral by Kyowa Hakko Kirin Co Ltd.

Orexo receives approval for Abstral in Japan
M2 - Fri Sep 20, 5:00AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday receipt of the approval for Abstral (fentanyl) sublingual tablets in Japan.

/C O R R E C T I O N -- Orexo U.S./
PR Newswire - Mon Sep 16, 9:04AM CDT
In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued 16-Sep-2013 by Orexo U.S. over PR Newswire, we are advised by the company that the phone number in the fifth paragraph and the Orexo U.S., Inc. boilerplate, should read "1-855-ZUBSOLV" rather than "1-888-ZUBSOLV" as originally issued inadvertently. The complete, corrected release follows:

Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence
PR Newswire - Mon Sep 16, 7:00AM CDT
Orexo U.S. announced today that Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII) are commercially available in pharmacies across the United States. In July 2013, Zubsolv received approval from the U.S. Food and Drug Administration (FDA) for the maintenance treatment of opioid dependence. Zubsolv should be used as part of a complete treatment plan, including counseling and psychosocial support.

Acute Pain - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Acute Pain
M2 - Thu Sep 05, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3cmj8z/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Pain. - A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AcelRx Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - AngioChem Inc. - Array BioPharma Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - CombinatoRx, Incorporated - Cytogel Pharma, LLC - Encore Therapeutics Inc. - Esteve Group - Grunenthal GmbH - Intas Pharmaceuticals Ltd. - Iroko Pharmaceuticals, LLC - Madeira Therapeutics - Menarini Group - Nektar Therapeutics - NeuroTherapeutics Pharma Inc. - Nuvo Research Inc. - Orexo AB - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - QRxPharma Limited - RaQualia Pharma Inc. - Sigma-Tau S.p.A. - Trevena, Inc. For more information visit http://www.researchandmarkets.com/research/3cmj8z/acute_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Migraine - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gndq/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2013" report to their offering. 'Migraine - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Migraine pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Allergan, Inc. Amgen Inc. Questcor Pharmaceuticals, Inc. BioDelivery Sciences International, Inc. Merck & Co., Inc. Biofrontera AG Dr. Reddy's Laboratories Limited Teva Pharmaceutical Industries Limited Zosano Pharma, Inc. Capnia, Inc. Revance Therapeutics, Inc. IntelGenx Technologies Corp. NovaDel Pharma, Inc. Paladin Labs Inc. POZEN Inc. Choongwae Pharma Corp Orexo AB D-Pharm Ltd. Ache Laboratorios Farmaceuticos S/A Alder Biopharmaceuticals Inc. CoLucid Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/47gndq/migraine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 159

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 44

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 8

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 100

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 103

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 75

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 119

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 74

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 0

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
APEC in Shenzhen Puts Trade Openness Back in Focus

Updated Category News Views 68

Shenzhen is hosting a familiar but consequential argument: prosperity gets harder to share when trade channels clog up. At the 33rd Asia-Pacific Economic Cooperation Economic Leaders' Meeting on November 18, President Xi Jinping used the opening of the APEC CEO Summit to argue for peace, openness, innovation, mutual benefit and support for the WTO-centered multilateral...

Continue Reading

Top 5 Most Recently Viewed Articles

Join Us for Engaging Insights at the Boston IT Summit

Updated Category News Views 115

On November 7th, the Boston Cloud Connect Summit brought together industry heavyweights to tackle pressing issues in cybersecurity and artificial intelligence. With tech's rapid evolution, you know this ain't just some run-of-the-mill conference; it’s a showcase of brains tackling real threats. Cybersecurity Insights: Joe Flores at the Helm Joe Flores, Massachusetts...

Continue Reading
Revolutionizing Fitness and Entertainment: HYROX Partners with Legendz

Updated Category News Views 306

HYROX Teams Up with Legendz for Unmatched Experiences HYROX, a leader in the world of fitness racing, has announced an exciting partnership with Legendz Social Sportsbook & Casino, aiming to merge the world of competitive fitness with top-tier entertainment. This collaboration will not only uplift the profile of fitness events but also enhance fan engagement like never...

Continue Reading
DXC Technology Teams with Ferrari for Advanced Automotive HMI

Updated Category News Views 210

DXC Technology Partners with Ferrari for Next-Gen HMI Development DXC Technology (NYSE: DXC) has entered a groundbreaking partnership with Ferrari aimed at transforming the driver experience through advanced Human Machine Interface (HMI) systems in the latest automotive models. This collaboration allows DXC to leverage its extensive expertise in the automotive sector to...

Continue Reading
CEO Aman Narang's Selling Decision Raises Investor Interest

Updated Category News Views 250

Understanding the Recent Insider Sale at Toast A recent SEC filing has brought to light an important transaction involving Aman Narang, the CEO of Toast (NYSE: TOST). On a notable day, Narang sold 1,732 shares of Toast, amounting to a total value exceeding $61,000. This insider action inevitably attracts the attention of seasoned investors and market observers alike....

Continue Reading
Blue Cross and Blue Shield of Montana: Quality Health Coverage For All

Updated Category News Views 259

Blue Cross and Blue Shield of Montana Enhances Health Offerings Blue Cross and Blue Shield of Montana (BCBSMT) is dedicated to providing quality individual and family health insurance plans across Montana as the open enrollment period commences. Experience and Availability of Plans For over 85 years, BCBSMT has been a cherished provider in Montana, actively extending its...

Continue Reading
om Blog Section End -->